{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT05318469","nct_id":"NCT05318469","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05318469. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients will receive balstilimab 450 mg or pembrolizumab 200 mg, IV, on Day 1 of each 3 week cycle and ivermectin at the assigned dose (see Section 5.1, Table 5.1.2), PO, Days 1-3, 8-10, 15-17 of each cycle (Days 1-3 of each week) until disease progression, intolerable toxicities, withdrawal of consent, or up to 35 treatments or 2 years of balstilimab or pembrolizumab, whichever comes first","label":"Treatment (ivermectin, balstilimab)","type":"EXPERIMENTAL"}],"collaborators":["Agenus Inc.","Gateway for Cancer Research"],"completion_date":{"date":"2026-10","type":"ESTIMATED"},"conditions":["Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Triple-Negative Breast Carcinoma","HR+ / HER2- Advanced Breast Cancer"],"enrollment":{"count":34,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Ivermectin","otherNames":["Sklice","Stromectol"],"type":"DRUG"},{"name":"Balstilmab","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-30","lead_sponsor":"Yuan Yuan","official_title":"A Phase I/II Study Evaluating the Safety and Efficacy of Ivermectin in Combination With Immune Checkpoint Inhibitor in Patients With Metastatic Triple Negative Breast Cancer and HR+/HER2- Metastatic Breast Cancer","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2026-10","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Incidence of adverse events","timeFrame":"From start of study treatment until 90 days after treatment completion"},{"measure":"Objective response rate","timeFrame":"From start of study treatment until disease progression, intolerable toxicities, or withdrawal of consent. Assessed up to 2 years."}],"references":[],"start_date":{"date":"2023-10-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer and HR+/HER2- Metastatic Breast Cancer","url":"https://clinicaltrials.gov/study/NCT05318469"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05318469"}